Opinion

Video

CAR T-cells as Third-line and Beyond Therapy for FL

Author(s):

Grzegorz S. Nowakowski, MD,Jennifer Crombie, MD

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute
Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center
Daniel J. DeAngelo, MD, PhD, chief of the Division of Leukemia and an institute physician at Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School
Julie M. Vose, MD, MBA
Alberto Chiappori, MD
Marco Davila, MD, PhD, the senior vice president and associate director for Translational Research in the Department of Medicine, as well as the Rustum Family Endowed Chair in Translational Research at Roswell Park Comprehensive Cancer Center
Nikolai Podoltsev, MD, PhD of Yale Cancer Center
4 experts are featured in this series.
Related Content
Image Credit: © Corona Borealis - stock.adobe.com
March 18th 2025

FDA Grants Orphan Drug Designation to Bexobrutideg in Waldenström Macroglobulinemia

Roxana S. Dronca, MD, professor, oncology, consultant, Division of Hematology/Oncology, Department of Internal Medicine, director, Mayo Clinic Comprehensive Cancer Center
January 20th 2025

FDA Approval Insights: Subcutaneous Nivolumab for Advanced Solid Tumors: With Roxana S. Dronca, MD

Orca-T in Hematologic Malignancies
March 17th 2025

Orca-T Improves cGVHD-Free Survival in Advanced Hematologic Malignancies

Onyee Chan, MD, hematologist/oncologist, Moffitt Cancer Center Magnolia Campus; Bradley D. Hunter, MD, medical director, Oncology, director, Immune Effector Cell Therapy, Intermountain Healthcare
December 24th 2024

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

Metastatic Colorectal Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 14th 2025

Mayo Clinic Researchers Identify Proteins Linked to Immunotherapy Resistance in Metastatic Colorectal Cancer

Casdatifan in ccRCC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 12th 2025

Casdatifan Monotherapy Shows Early Efficacy Signals and Tolerable Safety Profile in Pretreated ccRCC